CABA Cabaletta Bio Inc

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in four upcoming investor conferences in September:

• 2023 Wells Fargo Healthcare Conference: Members of management will be available for one-on-one meetings on Wednesday, September 6, 2023 in Boston, MA.
• Citi’s 18th Annual BioPharma Conference: Gwendolyn Binder, Ph.D., President of Science and Technology, will participate in a panel discussion titled “Cell Therapies in Autoimmune” on Thursday, September 7, 2023 at 1:50 p.m. ET in Boston, MA. Members of management will also be available for one-on-one meetings.
• H.C. Wainwright 25th Annual Global Investment Conference: Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat on Wednesday, September 13, 2023 at 8:30 a.m. ET in New York, NY. Members of management will also be available for one-on-one meetings.
• Morgan Stanley 21st Annual Global Healthcare Conference: Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat on Wednesday, September 13, 2023 at 2:15 p.m. ET in New York, NY. Members of management will also be available for one-on-one meetings.

A live webcast of the presentations will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.

About Cabaletta BioCabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in systemic lupus erythematosus and myositis, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.

Contacts:

Anup MardaChief Financial Officerinvestors@cabalettabio.com

William GramigStern Investor Relations, Inc.william.gramig@sternir.com